HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Curcumin Touted For Oral Health Gets EFSA Novel Food Nod

Executive Summary

In its latest batch of novel food assessments, the European Food Safety Authority gave the nod to a curcumin supplement touted for its oral health benefits, but rejected applications for flowering plant Tongkat Ali and water lentil Wolffia globosa.

You may also be interested in...



Japan’s Theravalues Clinical Trial Claims Curcumin Benefits For Common Cold

Japanese curcumin specialist Theravalues claims to have found via a randomized clinical trial that its Theracurmin and Theracurmin Super dietary supplements can help alleviate some symptoms of the common cold. “However, the level of evidence is weak,” they warn. “Additionally, because the study was based on the reporting of subjective cold-like symptoms, it is was unclear whether the symptoms were actual subjective symptoms caused by an upper respiratory tract infection.”

Protein-Rich Aquatic Plant Secures EU Novel Food Nod

The European Food Safety Authority has judged that Rubsico’s water lentils-based protein concentrate is safe as a novel food for use in dietary supplements and other products.

Italian Ministry Of Health Bans Turmeric Health Claims, Updates Product Labeling

Italy's Ministry of Health has ordered warnings be added to turmeric-based supplements and banned health claims following hepatitis cases relating their use. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel